Literature DB >> 23873254

Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye.

Peter A Karth1, Anne Chang, William Wirostko.   

Abstract

BACKGROUND: Factors predictive for response of diabetic macular edema (DME) to intravitreal bevacizumab (IVB) remain unclear. In this study, we assess the predictability of DME response to IVB based on the response to IVB in a previously treated fellow eye and other known pre-injection factors in (DME).
METHODS: Retrospective chart review was conducted on 28 patients (56 eyes) with bilateral DME who underwent bilateral IVB therapy. Responses in both eyes were measured by change in central subfield thickness (CSFT) via optic coherence tomography (OCT), and change in visual acuity. Age, lens status, and starting macular thickness were recorded.
RESULTS: We found 21 % of the reduction in CSFT after IVB on OCT in the study eye may be explained by the percentage change in CSFT in the previously treated fellow eye [CI: 0.092-0.716; p-value = 0.0141]. Also, the pre-injection CSFT predicts 14 % of the response to IVB in the same eye [R² = 9.6 %, p-value = 0.018]. When combined in a multi-factorial model, 33 % of the change in CSFT following IVB may be explained by these two factors. Lens status, change in visual acuity, and age were not statistically significant predictors of response.
CONCLUSIONS: In DME, the response to IVB in an eye is partially explained by the pre-injection retinal thickness in the same eye and by the response to IVB in the previously treated fellow eye. Lens status, change in visual acuity, and age were not statistically significant predictors of response in this study.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873254     DOI: 10.1007/s00417-013-2422-4

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  17 in total

1.  Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.

Authors:  Carsten H Meyer; Tim U Krohne; Frank G Holz
Journal:  Acta Ophthalmol       Date:  2010-02-16       Impact factor: 3.761

2.  Complications in patients after intravitreal injection of bevacizumab.

Authors:  Chiharu Shima; Hirokazu Sakaguchi; Fumi Gomi; Motohiro Kamei; Yasushi Ikuno; Yusuke Oshima; Miki Sawa; Motokazu Tsujikawa; Shunji Kusaka; Yasuo Tano
Journal:  Acta Ophthalmol       Date:  2007-11-17       Impact factor: 3.761

3.  A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.

Authors:  Ingrid U Scott; Allison R Edwards; Roy W Beck; Neil M Bressler; Clement K Chan; Michael J Elman; Scott M Friedman; Craig Michael Greven; Raj K Maturi; Dante J Pieramici; Michel Shami; Lawrence J Singerman; Cynthia R Stockdale
Journal:  Ophthalmology       Date:  2007-08-15       Impact factor: 12.079

4.  Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.

Authors:  Moosang Kim; Pyung Lee; Younggyun Kim; Seung-Young Yu; Hyung-Woo Kwak
Journal:  Ophthalmologica       Date:  2011-08-03       Impact factor: 3.250

5.  Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

Authors:  Quan Dong Nguyen; David M Brown; Dennis M Marcus; David S Boyer; Sunil Patel; Leonard Feiner; Andrea Gibson; Judy Sy; Amy Chen Rundle; J Jill Hopkins; Roman G Rubio; Jason S Ehrlich
Journal:  Ophthalmology       Date:  2012-02-11       Impact factor: 12.079

6.  Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment.

Authors:  Pei-Chen Wu; Chien-Hsiung Lai; Ching-Lung Chen; Chien-Neng Kuo
Journal:  J Ocul Pharmacol Ther       Date:  2011-10-12       Impact factor: 2.671

7.  Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab.

Authors:  Osamu Sawada; Hajime Kawamura; Masashi Kakinoki; Masahito Ohji
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-06-26       Impact factor: 3.117

8.  The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Arch Ophthalmol       Date:  1984-04

9.  The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema.

Authors:  R Klein; B E Klein; S E Moss; M D Davis; D L DeMets
Journal:  Ophthalmology       Date:  1984-12       Impact factor: 12.079

10.  Ten-year incidence of visual loss in a diabetic population.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Ophthalmology       Date:  1994-06       Impact factor: 12.079

View more
  2 in total

1.  Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema.

Authors:  Yoshiro Minami; Taiji Nagaoka; Akihiro Ishibazawa; Akitoshi Yoshida
Journal:  BMC Ophthalmol       Date:  2017-03-14       Impact factor: 2.209

2.  Subthreshold Photocoagulation Using Endpoint Management in the PASCAL® System for Diffuse Diabetic Macular Edema.

Authors:  Masafumi Hamada; Kishiko Ohkoshi; Keiji Inagaki; Nobuyuki Ebihara; Akira Murakami
Journal:  J Ophthalmol       Date:  2018-01-31       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.